Related Experiment Videos
[Hydroxyurea treatment for unresectable meningioma]
S Fuentes1, O Chinot, H Dufour
1Service de Neurochirurgie (Pr. F. Grisoli), Hôpital de La Timone Adulte, rue Saint-Pierre, 13385 Marseille 5. sfuentes@ap-hm.fr
Neuro-Chirurgie
|November 18, 2004
Summary
Hydroxyurea showed marginal efficacy in treating unresectable progressive meningioma, with only 7% objective response. New medical treatments are needed for this challenging condition.
Area of Science:
- Neuro-oncology
- Medical oncology
Background:
- Unresectable progressive meningioma management is challenging due to limited therapeutic options.
- Hydroxyurea has shown potential antitumoral effects, warranting further investigation.
Purpose of the Study:
- To evaluate the efficacy of hydroxyurea in patients with unresectable progressive meningioma.
- To assess objective response rates and tolerance of hydroxyurea therapy.
Main Methods:
- Prospective phase II study (1997-1999) of 43 patients with unresectable progressive meningioma.
- Continuous oral hydroxyurea (20 mg/kg/day) with follow-up via physical examination, CT/MRI, and blood tests every three months.
- Primary endpoint: objective response documented by MRI or CT.
Main Results:
- Only 3 out of 43 patients (7%) showed an objective response to hydroxyurea.
- Progressive disease was observed in 60.5% of patients.
- Hydroxyurea was generally well-tolerated, with anemia and asthenia being the most common side effects.
Conclusions:
- Hydroxyurea demonstrates marginal efficacy for meningioma and is not a substitute for surgery or radiotherapy.
- There is a continued need for effective medical treatments for progressive meningiomas.